Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy

This study has been completed.
Information provided by:
Bader, Ted, M.D. Identifier:
First received: September 4, 2008
Last updated: March 7, 2010
Last verified: March 2010
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.

Condition Intervention Phase
Chronic Hepatitis C
Drug: tamoxifen
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy

Resource links provided by NLM:

Further study details as provided by Bader, Ted, M.D.:

Primary Outcome Measures:
  • No significant changes in ALT or total bilirubin [ Time Frame: 14 days ]

Secondary Outcome Measures:
  • HCV RNA reduction [ Time Frame: 14 days ]

Estimated Enrollment: 18
Study Start Date: November 2008
Study Completion Date: October 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: tamoxifen
open label giving of tamoxifen
Drug: tamoxifen
giving drug tamoxifen
Other Name: Nolvadex

Detailed Description:
Six different dosages of tamoxifen will be given for 14 days with safety and viral loads being measured.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. HCV RNA positive.
  2. failed standard therapy

Exclusion Criteria:

  1. Cirrhosis on biopsy
  2. Severe medical or psychiatric conditions that would make the evaluation difficult
  3. Tamoxifen is a pregnancy category D drug so pregnant women must be excluded.
  4. Patients with coumadin cannot be used from a drug interaction.
  5. Active use of alcohol or illegal substances -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00749138

United States, Oklahoma
VA Hospital
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Bader, Ted, M.D.
Principal Investigator: Ted Bader OUHSC
  More Information

Responsible Party: Ted Bader, MD Identifier: NCT00749138     History of Changes
Other Study ID Numbers: 102453081873
Study First Received: September 4, 2008
Last Updated: March 7, 2010

Keywords provided by Bader, Ted, M.D.:
hepatitis C, tamoxifen

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Bone Density Conservation Agents processed this record on May 25, 2017